Back to Search Start Over

Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial.

Authors :
Felker GM
North R
Mulder H
Jones WS
Anstrom KJ
Patel MJ
Butler J
Ezekowitz JA
Lam CSP
O'Connor CM
Roessig L
Hernandez AF
Armstrong PW
Source :
Journal of cardiac failure [J Card Fail] 2023 Aug; Vol. 29 (8), pp. 1113-1120. Date of Electronic Publication: 2023 Jun 17.
Publication Year :
2023

Abstract

Background: Hospitalization due to heart failure (HFH) is a major source of morbidity, consumes significant economic resources and is a key endpoint in HF clinical trials. HFH events vary in severity and implications, but they are typically considered equivalent when analyzing clinical trial outcomes.<br />Objectives: We aimed to evaluate the frequency and severity of HF events, assess treatment effects and describe differences in outcomes by type of HF event in VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction).<br />Methods: VICTORIA compared vericiguat with placebo in patients with HF with reduced ejection fraction (< 45%) and a recent worsening HF event. All HFHs were prospectively adjudicated by an independent clinical events committee (CEC) whose members were blinded to treatment assignment. We evaluated the frequency and clinical impact of HF events by severity, categorized by highest intensity of HF treatment (urgent outpatient visit or hospitalization treated with oral diuretics, intravenous diuretics, intravenous vasodilators, intravenous inotropes, or mechanical support) and treatment effect by event categories.<br />Results: In VICTORIA, 2948 HF events occurred in 5050 enrolled patients. Overall total CEC HF events for vericiguat vs placebo were 43.9 vs 49.1 events/100 patient-years (P = 0.01). Hospitalization for intravenous diuretics was the most common type of HFH event (54%). HF event types differed markedly in their clinical implications for both in-hospital and post-discharge events. We observed no difference in the distribution of HF events between randomized treatment groups (P = 0.78).<br />Conclusion: HF events in large global trials vary significantly in severity and clinical implications, which may have implications for more nuanced trial design and interpretation.<br />Clinical Trial Registration: ClinicalTrials.gov (NCT02861534).<br /> (Copyright © 2023 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1532-8414
Volume :
29
Issue :
8
Database :
MEDLINE
Journal :
Journal of cardiac failure
Publication Type :
Academic Journal
Accession number :
37331690
Full Text :
https://doi.org/10.1016/j.cardfail.2023.04.015